Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) as Solithromycin Progresses to Phase 3 Studies in Japan
01 nov. 2016 07h30 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Third Quarter 2016 Financial Results and Provides Corporate Update
27 oct. 2016 16h15 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Third Quarter 2016 Financial Results
25 oct. 2016 16h15 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Presents Analysis Showing Rates of Failure for Existing CABP Antibiotics From Claims Database at Academy of Managed Care Pharmacy Meeting
04 oct. 2016 16h15 HE
|
Cempra, Inc.
—More than 20 percent of adult CABP patients failed initial antibiotic monotherapy, including approximately one of four elderly patients— —Average U.S. macrolide resistance to S. pneumoniae...
Cempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 Study
29 sept. 2016 16h15 HE
|
Cempra, Inc.
— Pre/post treatment biopsies confirm mean NAS reduction of 1.3 points after 90 days of treatment with solithromycin — — All six patients showed ALT reductions after 90 days of treatment with...
Cempra to Present at Three Upcoming Investor Conferences
01 sept. 2016 07h30 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra’s Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases
25 août 2016 16h05 HE
|
Cempra, Inc.
— Both pivotal Phase 3 studies now published in leading infectious disease journals — — FDA and EMA currently reviewing marketing applications for solithromycin for CABP in U.S. and EU — CHAPEL...
Cempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP
23 août 2016 07h30 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Appoints Dr. David Zaccardelli to Board of Directors
11 août 2016 16h05 HE
|
Cempra, Inc.
CHAPEL HILL, N.C., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Second Quarter 2016 Financial Results and Provides Corporate Update
01 août 2016 16h05 HE
|
Cempra, Inc.
Current cash balance now expected to fund operations through 2017 Management to host webcast and conference call today at 4:30 p.m. EDTCHAPEL HILL, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- ...